• linkedin
  • Increase Font
  • Sharebar

    Small Doses: The Weekly News You Need to Know

    News from the week of March 6 delivered to you.

     

    Medical Study

    Imatinib (Gleevec) Found to Be Effective After Over 11 Years

    Imatinib (brand name, Gleevec) has been found to retain its effectiveness against chronic myeloid leukemia (CML) after more than 11 years of treatment. A study published in the March 9 issue of The New England Journal of Medicine found that 83% of more than 500 CML patients who were treated with imatinib were still alive 10 years later. The study also found that there were no new long-term health risks to taking the drug in that time. Early studies of imatinib had raised concerns that long-term use could raise the risk of heart disease. Common side effects with the drug include nausea, muscle pain, fatigue, and pruritic rashes. The study was funded by Novartis, the maker of Gleevec.

    Hochhaus A, et al.: Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 2017; 376:917-927March 9, 2017. DOI: 10.1056/NEJMoa1609324.

    Previous Button

    Valerie DeBenedette
    Valerie DeBenedette is Managing Editor of Drug Topics.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available